Menu Search
Equities

Traws Pharma Inc

0T2:STU

Traws Pharma Inc

Actions
  • Price (EUR)6.05
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-58.98%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).

  • Revenue in USD (TTM)226.00k
  • Net income in USD-137.05m
  • Incorporated1998
  • Employees16.00
  • Location
    Traws Pharma Inc12 Penns TrailNEWTOWN 18940United StatesUSA
  • Phone+1 (267) 759-3680
  • Fax+1 (267) 759-3681
  • Websitehttps://www.onconova.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		TRAW:NAQ since
announced		Transaction
value
Trawsfynydd Therapeutics IncDeal completed01 Apr 202401 Apr 2024Deal completed-78.57%108.21m
Data delayed at least 15 minutes, as of Nov 11 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.